Department of Physiology, The North China Coal Medical University, Tangshan, Hebei Province, China.
Eur J Cancer Care (Engl). 2011 Jan;20(1):106-12. doi: 10.1111/j.1365-2354.2009.01148.x.
The Enhancer of Zeste homologue2 gene (EZH2) is frequently expressed at high levels in malignant tumours, including bladder cancer. It functions as a transcriptional regulator to the maintenance of cell identity, cell cycle regulation and oncogenesis. In the study, we detected EZH2 expression in bladder cancer tissues. These results showed EZH2 high expression in bladder cancer tissue at level of transcript and protein compared with normal bladder tissue and EZH2 expression correlated positively with tumour stage and grade. Then, we used RNA interference to inhibit EZH2 expression in bladder cancer EJ cell line. Efficient downregulation of EZH2 resulted in significantly decreased cell proliferation in EJ cells and retarded transition of G(1) phase to S phase. Our data suggest that EZH2 is involved in the tumourigenesis of bladder cancer and EZH2 downregulation contributes to inhibiting malignant growth by retarding cell entrance to S phase.
EZH2 基因（ Enhancer of Zeste homologue2）在包括膀胱癌在内的恶性肿瘤中经常高水平表达。它作为一种转录调节剂，维持细胞的身份、细胞周期的调节和致癌作用。在研究中，我们检测了膀胱癌组织中 EZH2 的表达。这些结果表明，与正常膀胱组织相比，膀胱癌组织中 EZH2 的转录本和蛋白水平高表达，EZH2 的表达与肿瘤分期和分级呈正相关。然后，我们使用 RNA 干扰抑制膀胱癌 EJ 细胞系中的 EZH2 表达。EZH2 的有效下调导致 EJ 细胞的增殖显著减少，并延缓 G1 期向 S 期的转变。我们的数据表明，EZH2 参与了膀胱癌的发生，EZH2 的下调通过延缓细胞进入 S 期来抑制恶性生长。
